Fresenius Medical Care AG & Co. KGaA (FMS)

Cash-generative dialysis operator with stable sales, improved FY2025 profitability, and meaningful liquidity backstops (including an undrawn revolving credit facility). The key offsets are reimbursement-policy exposure, regulatory/compliance complexity, and ongoing legal/investigation matters; interim results show softer net income, so this reads as a value-with-risk profile rather than a growth compounding story. Some market-derived fields (e.g., discounted-cash-flow outputs, beta, and Altman-style scores) could not be populated in this run due to a data-source outage; conclusions rely on SEC filings and reconstructed ratios.

Mixed two-sided setup: a fresh FDA warning letter on the Ogden sterile-injectables plant and JPMorgan's cut to Underweight weigh against a tape-rewarded parent Fresenius Q2 beat with raised 2026 guidance; the sentiment delta is a determinate but shallow deterioration (baseline +0.05 to scoring -0.04), and a moderate red-flag cap applies for conflicting catalyst signals. No severe flags; retail read indeterminate.

Score 2 (mostly neutral/weak bearish, bounce-only): price 22.22 sits below the SMA20 22.74, SMA50 23.64, SMA200 23.07 and the EMA9/21 stack 22.47/22.78, with MACD line/signal below zero (-0.35/-0.34), RSI14 37.36 (weak, not oversold) and ADX 20.16 (no trend). Mildly constructive only: RSI positive divergence vs 09-10 (29.5 at roughly unchanged price) and the 21.98-22.05 support zone held twice (09-17, 09-18); no confirmed reversal, so the chart cannot clear the 3 floor.